Skip to main content
. 2014 Nov 19;14:848. doi: 10.1186/1471-2407-14-848

Figure 2.

Figure 2

Changes of MUC1 and VEGF mRNA levels in blood of NSCLC patients. (A to C) Changes of MUC1 mRNA levels between before (B0) and 4 weeks after gefitinib treatment (B4w) in blood of NSCLC patients with partial response (PR), stable disease (SD) and progressive disease (PD). (D to F) Changes in blood VEGF mRNA levels between B0 and B4w time points in NSCLC patients with PR, SD and PD.